Handelsbanken Fonder
TPTX

Handelsbanken Fonder’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Handelsbanken Fonder’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,400
Closed -$557K – 1612
2022
Q2 		$557K Buy
+7,400
New +$329K ﹤0.01% 962
2022
Q1 		– Sell
-7,400
Closed -$353K – 1734
2021
Q4 		$353K Sell
7,400
-185,400
-96% -$8.29M ﹤0.01% 1558
2021
Q3 		$12.8M Buy
192,800
+21,000
+12% +$1.5M 0.07% 279
2021
Q2 		$13.4M Buy
171,800
+30,200
+21% +$2.23M 0.07% 272
2021
Q1 		$13.4M Buy
141,600
+1,200
+0.9% +$143K 0.08% 249
2020
Q4 		$17.1M Sell
140,400
-35,000
-20% -$3.83M 0.1% 202
2020
Q3 		$15.3M Buy
175,400
+80,000
+84% +$5.57M 0.11% 191
2020
Q2 		$6.16M Buy
+95,400
New +$5.5M 0.05% 298

Handelsbanken Fonder's TPTX Position: Q3 2022 in Review

Handelsbanken Fonder sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 7,400 shares — an estimated $557K sold.

Handelsbanken Fonder first reported a position in TPTX in Q2 2020 and held it in 8 quarters. The position peaked at $17.1M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Handelsbanken Fonder reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Handelsbanken Fonder sold 7,400 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $557K.
  • Handelsbanken Fonder first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
  • Handelsbanken Fonder's Turning Point Therapeutics, Inc. Common Stock position peaked at $17.1M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Handelsbanken Fonder's 13F filing for Q3 2022, filed 27 Oct 2022.